Advances in clinical outcomes: What we have learned during the COVID-19 pandemic

Our understanding of risk factors and interventions influencing outcomes from coronavirus disease 2019 (COVID-19) has continued to evolve, revealing advances emerging from hypotheses formed at the start of the pandemic. Epidemiologic studies have shown that asthma control, rather than a diagnosis of...

Full description

Bibliographic Details
Main Authors:	Al-Musa, A. (Author), Chou, J. (Author), Habiballah, S. (Author), LaBere, B. (Author), Nguyen, A.A (Author)
Format:	Article
Language:	English
Published:	Elsevier Inc. 2022
Subjects:	administration and dosage allergic reaction Antibodies, Monoclonal Antiviral Agents antivirus agent Article asthma Asthma azetidine derivative Azetidines baricitinib biological marker biological product Biological Products biologics Biomarkers clinical outcome coronavirus disease 2019 COVID-19 COVID-19 Vaccines cytokine cytokine receptor antagonist cytokine signaling drug effect drug efficacy drug safety drug tolerability genetic association genetic risk genetics human Humans IL 6 signaling IL6 protein, human immune deficiency Immunologic Deficiency Syndromes immunology Interleukin 1 Receptor Antagonist Protein interleukin 1 receptor blocking agent interleukin 6 Interleukin-6 Janus kinase inhibitor metabolism monoclonal antibody mortality pandemic pathogenicity prediction primary immunodeficiency prognosis Prognosis protein targeting purine derivative Purines pyrazole derivative Pyrazoles risk factor Risk Factors SARS-CoV-2 SARS-CoV-2 vaccine Severe acute respiratory syndrome coronavirus 2 siltuximab sulfonamide Sulfonamides survival analysis Survival Analysis treatment outcome Treatment Outcome virology
Online Access:	View Fulltext in Publisher

Internet

View Fulltext in Publisher

Advances in clinical outcomes: What we have learned during the COVID-19 pandemic

Internet

Similar Items